公司公告汇总 津药药业股份有限公司发布2024年年度权益分派实施公告，主要内容如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 A股每股现金红利0.098元。 股权登记日为2025年6月11日，除权（息）日和现金红利发放日均为2025年6月12日。 分红方案经2025年4月16日的2024年年度股东大会审议通过，以总股本1091886680股为基数，每股 派发现金红利0.098元（含税），共计派发107004894.64元。 无限售条件流通股的红利委托中国结算上海分公司派发，天津药业集团有限公司等三家股东的现 金红利由公司自行发放。 对于无限售条件流通股个人股东及证券投资基金，持股期限超过1年的暂免征收个人所得税；持股 1年以内的，暂不扣缴个人所得税，待个人转让股票时再计算应纳税额。 对于合格境外机构投资者（QFII）和香港联交所投资者，按照10%的税率代扣代缴企业所得税， 税后每股实际派发现金红利0.0882元。 公司联系方式：邮箱tjpc600488@vip.sina.com，地址天津开发区黄海路221号，电话022- 6 ...

证券代码：600488 证券简称：津药药业 公告编号：2025-034 津药药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 A 股每股现金红利0.098元 ? 相关日期 | 股份类别 | 股权登记日 | | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/11 | － | 2025/6/12 | 2025/6/12 | | ? 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 4 月 16 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 本次利润分配以方案实施前的公司总股本1,091,886,680股为基数，每股派发现金红利 （1）无限售条件流通股的红利委托中国结算上海分公 ...

证券代码：600488 证券简称：津药药业 公告编号：2025-034 津药药业股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 A 股每股现金红利0.098元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/11 | － | 2025/6/12 | 2025/6/12 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 4 月 16 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 重要内容提示： 每股分配比例 2. 自行发放对象 3. 分配方案： 本次利润分配以方案实施前的公司总股本1,091,886,680股为基数，每股派发现金红利 0.098 ...

Core Viewpoint - The article highlights the successful marketing strategy of Yilian, a skincare brand under Furuida Biotech, through its immersive "Spray Festival" event in Jinan, which aims to enhance brand recognition and consumer engagement while showcasing its technological advancements in skincare products [2][9][21]. Brand Strategy and Marketing - Yilian's "Spray Festival" serves as a key annual marketing event, emphasizing the brand's youthfulness and technological prowess, with a projected online GMV exceeding 1 billion in 2024, reflecting over 30% year-on-year growth [2][18]. - The event featured interactive installations and a strong visual design, transforming the functional aspect of hydration into an emotional experience centered around "dopamine" [9][21]. - The brand leveraged its global ambassador, Zhang Linghe, to attract attention and deepen consumer connections, marking his first offline appearance as Yilian's spokesperson [6][9]. Consumer Engagement - The festival included various interactive experiences, such as a "Spray Door" and a "Fog Language Mailbox," allowing fans to engage creatively and personally with the brand [4][6]. - The event's climax was marked by Zhang Linghe's participation, which significantly heightened fan excitement and engagement [6][9]. Pre-Event Marketing - Yilian initiated a comprehensive marketing campaign 30 days prior to the event, utilizing online and offline channels to create buzz and drive participation, resulting in over 60 million reads and 2 million discussions on social media [11][13]. - The brand executed targeted advertising in 14 cities, including outdoor displays and digital promotions, to maximize visibility and consumer interest [15][17]. Product Innovation and Market Position - Yilian holds a leading position in the facial spray market, with a 26.82% market share on Douyin and a 10 billion GMV target for 2024, supported by a robust framework of technology research, market insight, and cultural narrative [18][19]. - The brand's commitment to technological innovation is evident in its product upgrades, such as the introduction of dual-patent hyaluronic acid and a new product line featuring a unique water/powder separation design [19][20]. Cultural Narrative - Yilian emphasizes a dual narrative of "technology + culture," rooted in its historical and cultural origins in Jinan, which enhances its brand identity and consumer connection [20][21]. - The "Spray Festival" reinforces this narrative by integrating product demonstrations, fan interactions, and emotional engagement, solidifying the brand's position in the skincare industry [21].

Core Viewpoint - The company held its 2024 annual performance briefing on May 16, 2025, to discuss financial status, market expansion, development strategy, and corporate governance with investors [1] Group 1: Company Performance - In 2024, the company achieved an operating income of 3.215 billion yuan and a net profit attributable to shareholders of 133 million yuan, representing a year-on-year growth of 14.01% [2] Group 2: Strategic Focus - The company will continue to adhere to an integrated development strategy for raw materials and formulations, focusing on high-quality development, steady progress, and operational efficiency [2][4] - The company aims to enhance its product pipeline, accelerate diversified and differentiated product development, and optimize its research-production-sales management model [2][5] Group 3: Market Expansion - The company is strengthening its presence in both domestic and international markets by optimizing marketing models and enhancing terminal development and academic promotion [4] - The overseas performance is driven by maintaining market share through key partnerships and flexible pricing strategies, as well as deepening engagement in emerging markets [2][4] Group 4: Management and Governance - The company emphasizes internal management improvements, focusing on energy conservation, efficiency enhancement, and lean management to drive cost reduction and efficiency [4] - The company is committed to protecting investor rights and has increased its cash dividend ratio to over 80% for both 2023 and 2024 profit distribution plans [2]

一、说明会召开的情况 公司于2025年3月27日在《上海证券报》《中国证券报》和上海 证券交易所网站披露了《津药药业股份有限公司2024年年度报告》， 并于2025年5月9日披露了《津药药业股份有限公司关于召开2024年度 业绩说明会的公告》（2025-031#）。 2025年5月16日13:00-14:45，公司董事长徐华先生、总经理李书 箱先生、独立董事边泓先生、独立董事陈喆女士、首席财务官朱立延 先生、董事会秘书刘博先生共同出席了2024年度业绩说明会，针对公 司财务状况、市场开拓、发展战略、公司治理等方面与投资者互动交 流和沟通，在信息披露允许的范围内就投资者关注的问题进行了回答。 二、投资者提出的问题及公司回复情况 公司对投资者在本次说明会上主要关注的问题进行了回复，具体 情况如下： 证券代码：600488 证券简称：津药药业 编号：2025-033 津药药业股份有限公司 关于 2024 年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）于20 ...

Core Viewpoint - Three pharmaceutical companies, Xianju Pharmaceutical, Tianjin Pharmaceutical, and Lianhuan Pharmaceutical, have been penalized for monopolistic practices related to the raw material dexamethasone sodium phosphate, with total fines amounting to approximately 325 million yuan [1][2][3]. Group 1: Penalties and Financial Impact - Xianju Pharmaceutical was fined a total of approximately 195 million yuan, which includes the confiscation of illegal gains of 23.74 million yuan and a fine of about 172 million yuan based on 8% of its 2023 sales [2][5]. - Tianjin Pharmaceutical faced penalties totaling approximately 69.19 million yuan, including the confiscation of illegal gains of 42.76 million yuan and a reduced fine of about 13.2 million yuan after an 80% reduction [3][5]. - Lianhuan Pharmaceutical was fined approximately 61.04 million yuan, which includes the confiscation of illegal gains of 17.89 million yuan and a reduced fine of about 61.63 million yuan after a 30% reduction [3][5]. Group 2: Profitability Impact - The fines significantly impact the profitability of the companies, with Tianjin Pharmaceutical's penalties representing 2.15% of its recent audited revenue and 51.85% of its net profit attributable to shareholders [5]. - For Xianju Pharmaceutical, the total fine of 195 million yuan accounts for 4.87% of its projected 2024 revenue of 4 billion yuan and 49.17% of its net profit of 397 million yuan [5]. - Lianhuan Pharmaceutical's proposed fines represent 72.53% of its net profit of 84 million yuan for the previous year [5]. Group 3: Recurrence of Violations - Tianjin Pharmaceutical has been penalized for monopolistic behavior for the fourth time in four years, with cumulative fines exceeding 170 million yuan [6][7].

Core Viewpoint - Four companies engaged in a price-fixing conspiracy for dexamethasone phosphate raw materials, leading to significant price increases and resulting in administrative penalties exceeding 350 million yuan [1][5][15] Group 1: Companies Involved - The companies involved in the price-fixing conspiracy are Tianjin Pharmaceutical Industry Co., Ltd. (津药药业), Xianju Pharmaceutical Co., Ltd. (仙琚制药), Lianhuan Pharmaceutical Co., Ltd. (联环药业), and Xi'an Guokang Ruijin Pharmaceutical Co., Ltd. (西安国康瑞金) [1][5][14] - The main organizer of the conspiracy was identified as an individual named Guo, who facilitated communication and coordination among the companies [5][6] Group 2: Price Changes - The price of dexamethasone phosphate raw materials increased from several thousand yuan per kilogram to over ten thousand yuan, with some companies raising prices as high as 38,000 yuan per kilogram [1][10][14] - Specific price increases included Tianjin Pharmaceutical raising prices from a maximum of 9,000 yuan to 13,800 yuan per kilogram, and Xi'an Guokang Ruijin increasing prices from 7,900 yuan to between 10,000 and 38,000 yuan per kilogram [10][14] Group 3: Administrative Penalties - The total penalties imposed on the companies amounted to over 350 million yuan, with Tianjin Pharmaceutical fined 69.19 million yuan, Xianju Pharmaceutical fined 195.3 million yuan, and Xi'an Guokang Ruijin fined 28.78 million yuan [1][12][13] - Lianhuan Pharmaceutical is expected to face a fine of 61.04 million yuan, with a proposed reduction of 30% due to its cooperation during the investigation [1][11] Group 4: Cooperation and Leniency - Tianjin Pharmaceutical was the first to submit a leniency application, providing crucial evidence and reporting the details of the price-fixing agreement, which led to an 80% reduction in its fine [2][11] - In contrast, Xianju Pharmaceutical and Xi'an Guokang Ruijin did not submit leniency applications, resulting in no reductions in their fines [2][12][14]

Group 1 - The core issue involves Xianju Pharmaceutical (002332) receiving an administrative penalty from the Tianjin Municipal Market Supervision Administration for engaging in a monopoly agreement to fix the price of Dexamethasone Phosphate Sodium raw materials, violating Article 17(1) of the Anti-Monopoly Law of the People's Republic of China [1] - The company is ordered to cease illegal activities and faces a total penalty of RMB 195,296,912.22, which includes the confiscation of illegal gains amounting to RMB 23,746,680.00 and a fine of RMB 171,550,232.22, equivalent to 8% of its 2023 sales [1] - Other companies involved in the same matter, including Tianyao Pharmaceutical (600488.SH) and Lianhuan Pharmaceutical (600513.SH), were also penalized, with fines of RMB 69,192,400 and RMB 61,038,200 respectively [3]

Group 1 - China National Pharmaceutical plans to acquire 100% equity of Jinsui Technology for 302 million yuan to enhance marketing and supply chain management capabilities [1] - The acquisition aims to strengthen the company's e-commerce platform, product pipeline, and marketing strategies, potentially boosting investor confidence and stock performance [1] Group 2 - Tianjin Pharmaceutical responded to an inquiry regarding its 2024 annual report, highlighting strategic R&D collaborations and significant reductions in sales expenses due to policy changes and marketing upgrades [2] - The reduction in sales expenses indicates improved cost control and operational efficiency, which may positively impact investor confidence and stock valuation [2] Group 3 - President Trump announced plans to sign an executive order aimed at reducing prescription drug prices by 30% to 80%, aligning U.S. drug prices with the lowest global prices [3] - A significant drop in U.S. drug prices could pressure domestic pharmaceutical companies' export businesses, but innovative domestic firms may leverage unique advantages to mitigate risks [3] Group 4 - Fosun Pharma's FCN-159 tablet has been included in the breakthrough therapy designation program, indicating strong R&D capabilities and market potential for treating rare diseases and tumors [4] - The breakthrough designation may accelerate the drug's development and approval process, enhancing investor confidence and potentially increasing the company's market competitiveness [4] Group 5 - Rongchang Biopharma's ADC drug, RC48, has successfully met primary endpoints in a Phase III clinical trial for treating advanced or metastatic urothelial carcinoma [5] - The successful trial results may expand the drug's indications and significantly enhance its market competitiveness and commercial value, attracting investor interest [6]